In conclusion, through different anti-tumoral mechanisms, such as increasing ROS and inhibiting the Cox-2 mediated NF-κB pathway, phloretin might have potential in providing the next medication for AR-dependent or independent PCa. This evidence concerns the gene PTGS2 and posterior cortical atrophy.